← Eichor
Study identifier: NCT05017766 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria

Condition: Antimicrobial Resistance (AMR)  ·  Sponsor: University Hospital, Basel, Switzerland

PhaseN/A
Planned participants8000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel. It is to investigate antimicrobial resistance (AMR) including three clinical manifestations of infectious diseases: urinary tract infection, pneumonia and deep-seated infections. The focus is on four bacteria (E. coli, Klebsiella species, S. aureus, P. aeruginosa) that are part of the high priority list of World Health Organization (WHO). Residual patient samples are analysed for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS) and immunophenotyping and exploration of bacterial properties.

This description comes directly from the study's public registry record.

Talk to the study team

Nina Khanna, Prof.  ·  +41 61 328 73 25  ·  nina.khanna@usb.ch

Christoph Dehio, Prof.

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital BaselBasel, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05017766